We are live on
!
Find out more
ESPR
Esperion Therapeutics
ESPR
ESPR
Delisted
ESPR was delisted on the 10th of July, 2026.
172 hedge funds and large institutions have $1.62B invested in Esperion Therapeutics in 2019 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
150% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 18
64% more capital invested
Capital invested by funds: $991M → $1.62B (+$631M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more call options, than puts
Call options by funds: $40.9M | Put options by funds: $30.3M
34% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 41
13% more funds holding
Funds holding: 152 → 172 (+20)
2.42% more ownership
Funds ownership: 99.48% → 101.9% (+2.4%)
Holders
172
Holders Change
+20
Holders Change %
+13.16%
% of All Funds
3.39%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.12%
New
45
Increased
55
Reduced
41
Closed
18
Calls
$40.9M
Puts
$30.3M
Net Calls
+$10.6M
Net Calls Change
+$5.12M
Top Buyers
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$15.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.4M |
| 4 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$10.1M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$6.67M |
